Mosaic Immunoengineering Inc
Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on advancing and commercialization of immunotherapies for the treatment of cancer. It engages in pursuing new product candidates and platforms to build a new pipeline based on immunotherapies. Mosaic ImmunoEngineering, Inc. was founded in 2020 and is based in Huntington Beach, California.
Mosaic Immunoengineering Inc (CPMV) - Total Assets
Latest total assets as of September 2025: $55.30K USD
Based on the latest financial reports, Mosaic Immunoengineering Inc (CPMV) holds total assets worth $55.30K USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Mosaic Immunoengineering Inc - Total Assets Trend (2016–2024)
This chart illustrates how Mosaic Immunoengineering Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Mosaic Immunoengineering Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Mosaic Immunoengineering Inc's total assets of $55.30K consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 81.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Mosaic Immunoengineering Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Mosaic Immunoengineering Inc's current assets represent 100.0% of total assets in 2024, an increase from 88.2% in 2016.
- Cash Position: Cash and equivalents constituted 81.2% of total assets in 2024, up from 26.1% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Mosaic Immunoengineering Inc Competitors by Total Assets
Key competitors of Mosaic Immunoengineering Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Mosaic Immunoengineering Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Mosaic Immunoengineering Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Mosaic Immunoengineering Inc is currently not profitable relative to its asset base.
Mosaic Immunoengineering Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.01 | 0.01 | 0.56 |
| Quick Ratio | 0.01 | 0.01 | 0.56 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-5.86 Million | $ -5.26 Million | $ -372.93K |
Mosaic Immunoengineering Inc - Advanced Valuation Insights
This section examines the relationship between Mosaic Immunoengineering Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.33 |
| Latest Market Cap to Assets Ratio | 3.76 |
| Asset Growth Rate (YoY) | -21.1% |
| Total Assets | $141.61K |
| Market Capitalization | $532.92K USD |
Valuation Analysis
Premium Asset Valuation: The market values Mosaic Immunoengineering Inc's assets at a significant premium ( 3.76x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Mosaic Immunoengineering Inc's assets decreased by 21.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Mosaic Immunoengineering Inc (2016–2024)
The table below shows the annual total assets of Mosaic Immunoengineering Inc from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $141.61K | -21.12% |
| 2023-12-31 | $179.53K | -31.29% |
| 2022-12-31 | $261.28K | -3.05% |
| 2021-12-31 | $269.49K | -41.13% |
| 2020-12-31 | $457.80K | -44.08% |
| 2019-12-31 | $818.62K | -57.47% |
| 2018-12-31 | $1.92 Million | -25.39% |
| 2017-12-31 | $2.58 Million | -31.41% |
| 2016-12-31 | $3.76 Million | -- |